HAE

No analysis generated yet. Run the pipeline for this company.

AI-extracted key facts from press releases and SEC filings. Significance 1–10.

6

EarningsNeutralPer-CompanyMar 12, 2026

Orchestra BioMed reports $33.5M 2025 revenue, $106.5M cash position for pivotal trials

▸2025 non-recurring revenue $33.5M driven by Terumo Virtue SAB agreement
▸Cash position $106.5M as of December 31, 2025
▸Expected $35M inflow in Q2 2026 from Medtronic, Ligand, and Haemonetics transactions
▸BACKBEAT global pivotal study enrollment accelerated following Q4 protocol amendments
▸Virtue SAB U.S. pivotal trial initiated in Q4 2025

Haemonetics